

Ipsen UK & Ireland sets out bold vision with appointment of Asad Mohsin Ali as General Manager

Appointment adds over two decades of commercial experience to the Ipsen team as it seeks to build on strong H1 results to expand its global footprint

Key UK & Ireland strategic priorities to include expansion of UK as Global hub, continued commercial growth, and strengthening Ipsen's position as partner of choice to healthcare services and patients

SLOUGH, UK, 3 September 2018 — Ipsen (Euronext: IPN; ADR: IPSEY) today announced the appointment of Asad Mohsin Ali as General Manager of its UK & Ireland affiliate. Asad – who joins from his former role as VP & General Manager for the UK, Ireland and Nordics at TESARO – will lead Ipsen's rapidly growing commercial presence in the UK & Ireland. Bringing a wealth of experience across key areas for Ipsen including oncology, haematology and rare diseases, Asad will act as Head of Site for their Global Hub in Bath Road, Slough, as well as Chair of Ipsen's UK management forum, enabling close alignment with Ipsen's R&D centre in Oxford and manufacturing site in Wrexham. This One Ipsen approach will drive the realisation of the company's vision to be a leading Global biotech company focused on innovation and specialty care.

"I am delighted to be joining an exceptional Ipsen team," said Asad Mohsin Ali. "The growth and global expansion of this company over recent years is testament to the desire that each and every individual has to be part of meaningful change for patients, doctors and health services. We have real potential to build on our UK & Ireland footprint over the coming years and my desire is that we create a true global hub for innovation across this region, building on the impressive Global talent that exists in the UK."

Asad has spent over two decades driving innovation and commercial growth across the pharmaceutical industry. Most recently, since 2016 he has been acting as VP and General Manager for the UK, Ireland and Nordics at TESARO, specialising in oncology and overseeing the launch and successful UK reimbursement of its cutting-edge PARP inhibitor in recurrent ovarian cancer. Prior to his time at TESARO Asad spent 17 years at Novartis working across various Global and country roles including in the UK, Switzerland and Mexico.

Commenting on the appointment, Harout Semerjian, Executive Vice-President, Ipsen Chief Commercial Officer said: *"Asad is motivated by exceeding his external and internal stakeholders' expectations and has demonstrated strong leadership skills in all roles to date. He has had the opportunity to work across the full spectrum of the drug lifecycle, from discovery to patent expiry, and his operational & strategic experiences will be vital assets that will help propel Ipsen UK & Ireland to the next level of continued growth and best places to work."*

Asad succeeds Ewan McDowall who will now act as Head of Asia (excl China), Specialty Care out of Singapore.

ENDS

For further information, please contact:

Jess Smith, Head of Communications, UK & Ireland

T: +44 (0) 7557 267634

E: jess.smith@ipsen.com

MEDIA ALERT
3 September 2018



Tim Cockroft, Director, akt health communications
T: +44 (0)7957 325 583
E: tim@akthealthcomms.com

Ipsen in the UK

Our team in the UK is a core part of Ipsen's global biopharmaceutical business and are driven by the belief that patients don't have time to wait. We have a biotech mindset coupled with pharmaceutical capabilities and have invested in a robust business presence in the UK that spans the early stages of R&D (Abingdon, Oxford) through to in-house manufacturing (Wrexham, Wales) so we can effectively deliver on our promise to UK patients. As part of this investment in the heart of UK life sciences, we employ over 600 people across our three major UK sites, including our commercial headquarters in Bath Road, Slough.

Our business focuses on oncology, neurosciences and rare diseases, to create innovative therapies in areas of high unmet medical need. In the UK we already provide best-in-class treatments for a range of conditions, including renal cell carcinoma and neuroendocrine tumours, where there are limited treatment options available for patients. In addition to the eight treatments we have already made available to patients in the UK, our team is continuing to research, develop and commercialise new assets to urgently address the needs of patients who are still waiting.